Skip to content

Trial Summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously.

Acronym:

STOP-GAP

ACTRN/NCT /ethics:

NCT02821013

Scientific title:

A Randomized Phase-III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Sponsor / Cooperative group:

Canadian Cancer Trials Groups

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream Melanoma
Cancer StageMetastatic or Widespread
Anticipated Start DateN/A
Anticipated End DateN/A

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting